Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
47
SLNCF Quote, Financials, Valuation and Earnings
Last price:
$1.75
Seasonality move
:
-3.27%
Day range:
$1.75 - $1.75
52-week range:
$0.50 - $2.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
123.28x
P/B ratio:
3.35x
Volume:
--
Avg. volume:
148
1-year change:
19.05%
Market cap:
$248M
Revenue:
$43.3M
EPS (TTM):
-$0.79
Analysts' Opinion
-
Consensus RatingSilence Therapeutics Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Silence Therapeutics Plc has an estimated downside of -- from its current price of $1.75.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $1.75.
Fair Value
-
According to the consensus of 1 analyst, Silence Therapeutics Plc has -- downside to fair value with a price target of -- per share.
SLNCF vs. S&P 500
-
Over the past 5 trading days, Silence Therapeutics Plc has overperformed the S&P 500 by 9.52% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Silence Therapeutics Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Silence Therapeutics Plc revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Silence Therapeutics Plc reported revenues of $159K.
Earnings Growth
-
Silence Therapeutics Plc earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Silence Therapeutics Plc reported earnings per share of -$0.15.
Enterprise value:
146M
EV / Invested capital:
--
Price / LTM sales:
123.28x
EV / EBIT:
--
EV / Revenue:
72.64x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-2.05x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.1M
Return On Assets:
-58.13%
Net Income Margin (TTM):
-5571.16%
Return On Equity:
-101.79%
Return On Invested Capital:
-101.67%
Operating Margin:
-14881.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $34.3M | $20.5M | $2M | $1.5M | $159K | |
| Gross Profit | $18.4M | $9.1M | -$2.1M | -$2.1M | -$20.5K | |
| Operating Income | -$58M | -$72M | -$99M | -$29.3M | -$23.7M | |
| EBITDA | -$57.4M | -$71.4M | -$98.4M | -$29.1M | -$23.5M | |
| Diluted EPS | -$0.48 | -$0.56 | -$0.79 | -$0.25 | -$0.15 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $111.6M | $126.7M | $106.9M | $211.3M | $133.6M | |
| Total Assets | $124.5M | $138.5M | $119.5M | $227.2M | $146.8M | |
| Current Liabilities | $24.7M | $28.9M | $22M | $22.7M | $17.4M | |
| Total Liabilities | $102.6M | $100.4M | $95.1M | $100.4M | $72.7M | |
| Total Equity | $22M | $38.1M | $24.4M | $126.8M | $74.1M | |
| Total Debt | -- | $557K | $384.4K | $186.4K | $97K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$49.2M | -$53.6M | -$71.1M | -$25M | -$11.1M | |
| Cash From Investing | $375.6K | -$88.1M | -$32.6M | -$38.1M | $52.8M | |
| Cash From Financing | $19.3M | $154.2M | $7.8M | $7.8M | -- | |
| Free Cash Flow | -$49.6M | -$53.8M | -$71.2M | -$25M | -$11.1M | |
SLNCF
Sector
Market Cap
$248M
$25.5M
Price % of 52-Week High
77.78%
50%
Dividend Yield
0%
0%
Shareholder Yield
-3.8%
-1.62%
1-Year Price Total Return
19.05%
-17.47%
Beta (5-Year)
0.764
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.68
200-day SMA
Buy
Level
$1.61
Bollinger Bands (100)
Buy
Level
1.44 - 1.92
Chaikin Money Flow
Buy
Level
2K
20-day SMA
Buy
Level
$1.63
Relative Strength Index (RSI14)
Buy
Level
75.73
ADX Line
Buy
Level
25.65
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$1.62
MACD (12, 26)
Buy
Level
0.46
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.393)
Sell
CA Score
(Annual)
Level (-1.8198)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.0818)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
Stock Forecast FAQ
In the current month, SLNCF has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SLNCF average analyst price target in the past 3 months is --.
-
Where Will Silence Therapeutics Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Silence Therapeutics Plc share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Silence Therapeutics Plc?
Analysts are divided on their view about Silence Therapeutics Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Silence Therapeutics Plc is a Sell and believe this share price will rise from its current level to --.
-
What Is Silence Therapeutics Plc's Price Target?
The price target for Silence Therapeutics Plc over the next 1-year time period is forecast to be -- according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SLNCF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Silence Therapeutics Plc is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SLNCF?
You can purchase shares of Silence Therapeutics Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Silence Therapeutics Plc shares.
-
What Is The Silence Therapeutics Plc Share Price Today?
Silence Therapeutics Plc was last trading at $1.75 per share. This represents the most recent stock quote for Silence Therapeutics Plc. Yesterday, Silence Therapeutics Plc closed at $1.75 per share.
-
How To Buy Silence Therapeutics Plc Stock Online?
In order to purchase Silence Therapeutics Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SLNCF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SLNCF
Sector
P/E ratio
--
22.53x
PEG ratio
-0.02x
-0.01x
P/B ratio
3.35x
1.79x
Price / LTM sales
123.28x
1.52x
Growth Metrics
SLNCF
Sector
Revenue growth
-78.93%
3.33%
Earnings growth
-5.64%
12%
Revenue (5-year growth)
168.28%
6.38%
Earnings forecast
-$0.15
-$0.20
Profitability
SLNCF
Sector
Profitability FY 2024
$31.2M
$2.1M
Return on invested capital
-101.67%
-33.43%
Return on assets
-58.13%
-29.79%
Return on equity
-101.79%
-39.36%
Earnings Date
Last Earnings Date
Mar
5
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Jun
4
Balance Sheet
SLNCF
Sector
Total cash
$102.2M
$24.1M
Short term investments
$26M
$23.2M
Total assets
$202.6M
$69.8M
Long term debt
$97K
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 6.21% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 7.08% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 7.28% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
